Skip to search formSkip to main content

Oxi8006

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.
This study describes the vascular disrupting ability and the mechanism of action of the indole-based tubulin-binding compound… Expand
Is this relevant?
2015
2015
Vascular Disrupting Activity of OXi8006 in Endothelial Cells and Its Phosphate Prodrug OXi8007 in Breast Tumor Xenografts in Vivo
Tubulin-binding, small-molecule vascular disrupting agents (VDAs) are anticancer agents that rapidly depolymerize microtubules… Expand
Is this relevant?
2013
2013
Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole…
The discovery of a 2-aryl-3-aroyl indole-based small-molecule inhibitor of tubulin assembly (referred to as OXi8006) inspired the… Expand
Is this relevant?
2013
2013
Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.
The natural products colchicine and combretastatin A-4 are potent inhibitors of tubulin assembly, and they have inspired the… Expand
Is this relevant?
2012
2012
Structural Modifications of OXi8006 Leading to New Indole-Based Anti-Cancer Agents
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE